If this message is not displayed correctly, click here.

ERA-EDTA Flash
 

ERA-EDTA FLASH is the official ERA-EDTA E-NEWSLETTER

No 158, October 2018

 

Editor in Chief: María José Soler Romeo - Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini

ERA-EDTA Headquarters - Via XXIV Maggio, 38 - 43123 Parma - Italy

 
Education
Research
Institutional
Association
 
Education
ERA-EDTA 2018 industry symposia
Learn more about high-volume HDF and SGLT2 inhibitors use from the webcasts of two ERA-EDTA 2018 industry symposia

During the 55th ERA-EDTA Congress 2018 in Copenhagen, the following two industry symposia (the first about high-volume HDF supported by Fresenius Medical Care and the second about SGLT2 inhibitors organised by UCL Centre for Nephrology) were presented:

  1. High-volume HDF: Time to shift the renal replacement paradigm and improve patient outcomes (Supported by Fresenius Medical Care)
    Topics: “What is the evidence for improved outcomes with high-volume HDF”, “How to successfully prescribe, implement and achieve high-volume HDF?” and “What did we learn about high-volume HDF in high risk patient populations”.
    Find the webcasts and available presentations on the ENP here.
  2. SGLT2 inhibitors of today for the renal patient of tomorrow – does the future look bright? (Organised by the UCL Centre for Nephrology, Royal Hospital)
    Topics: “Let’s meet the renal patient of today – A changing profile for the future?”, “SGLT2 inhibitors for our renal patients of today and tomorrow – Does the future look bright?” and “Bringing the pieces together – Understanding the mechanisms of SGLT2 inhibitors”.
    Find the webcasts on the ENP here.

    You can find all available industry symposia in addition to other topics on the ENP here.
 
Research
Just published online: read the latest NDT article
Prognostic impact of nutrition, anaemia, bone metabolism and cardiovascular comorbidities on elderly HD patients
By using SEMs, researchers attempted to model a single variable for nutrition, CKD complications and cardiovascular comorbidities were analysed to compare their relative impact on elderly HD patients’ survival.

Read more→
 
NDT - Article of the week
Merits and caveats of propensity scores to adjust for confounding
Propensity score matching is increasingly used in epidemiology. The authors summarise benefits and pitfalls for this type of analysis, and provide practical examples based on data from the NECOSAD study. The paper is accessible here free of charge until this Sunday at 23.59 (UK time). Do not miss it!
 
EUDIAL
Keen on getting involved in Incremental Haemodialysis?
Why not take the survey created by Prof. C. Basile (EUDIAL Chair) - it is available here
The majority of patients on dialysis are currently treated with a fixed dose thrice-weekly haemodialysis regimen irrespective of whether or not they are starting dialysis therapy (incident) or have been receiving dialysis for some time (prevalent) and without taking into consideration their residual kidney function (RKF). The thrice-weekly regimen has been assumed almost as a dogma in the dialysis community. Incredibly, this schedule has been widely accepted worldwide without ever undergoing any randomised controlled trial to examine whether less frequent haemodialysis treatments would be inadequate or harmful.
Read more and access the survey here.
 
Contact Us
 
Web Site
 
E-Mail
 
Facebook
 
Twitter
 
Google+
 
LinkedIn
 
Instagram
 
YouTube
 
Vimeo
 
 
Image

Initiatives

 
Image

Working Groups

...and their latest initiatives:

 
Image

Committees...

 
Image
Opportunities
 
Image

The advantages of being a member of ERA-EDTA

As a member you will become part of one of the
most influential European Medical Associations!

 

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.